Skip to content

Contact Us

Contact Us

Ovarian Cancer Research Alliance

Mailing Address
45 Rockefeller Plaza, 20th Floor, New York, NY 10111
212-268-1002

Washington DC Office
1101 14th Street NW, Suite 850, Washington, DC 20005
866-399-6262 (Toll Free) | 202-331-2292 (Fax)

info@ocrahope.org

Donations

Make an online donation today.

Mail your contributions to the address below:

Ovarian Cancer Research Alliance
Post Office Box 32141
New York, NY 10087-2141

Tax ID #13-3806788

Patient Support Line

We’re here for you! Our Patient Support team is available to take your calls Monday – Friday. Call 212-268-1002 and if no one is available when you call, someone will get back to you within 24 hours.

Press

For all press inquiries, please contact:

Amanita Duga-Carroll

ADC Strategic Communications, Inc.

917-597-7880
adcstrategiccomms@gmail.com

Related Topics

Cool Hand Frank Names OCRA Featured Cause for March

Cool Hand Frank Names OCRA Featured Cause for March

Cool Hand Frank, a digital publication that spotlights nonprofits making a difference, has named Ovarian Cancer Research Alliance (OCRA) its featured cause for March 2026, spotlighting OCRA’s work in advancing ovarian and gynecologic cancer research and supporting patients and their loved ones. The publication cited a deeply personal connection to the cause, with the author … Continued

Read more

The Overview: February 2026

The Overview: February 2026

The Global Ovarian Cancer Research Consortium and its inaugural AI Accelerator Grant have been making waves across health, science, and business media, reflecting widespread interest in what this work could mean for patients. The $1 million global research grant, plus an additional $1 million in compute support from Microsoft’s AI for Good Lab, will fund … Continued

Read more

Stay Informed

Get email updates about research news, action alerts, and ways to join the fight.

We care about your data. Read our privacy policy.

Our website uses cookies to ensure you get the best experience. By continuing to use this website, you indicate that you have read and agree to our Terms of Use and Privacy Policy.